April 2024

Deucravacitinib, a selective, allosteric tyrosine kinase 2 inhibitor, in scalp psoriasis: A subset analysis of two Phase 3 randomized trials in plaque psoriasis

Am Acad Dermatol 2023. doi: 10.1016/j.jaad.2023.11.060

This pooled analysis of the Phase 3 PSO-1 and PSO-2 trials shows that deucravacitinib has greater efficacy in treating scalp PsO than placebo and apremilast. At week 16, response rates were greater with deucravacitinib versus placebo or apremilast for scalp-specific Physician Global Assessment 0/1 and Psoriasis Scalp Severity Index. Efficacy was maintained through 52 weeks in patients who received continuous deucravacitinib treatment.

Keywords:

Bimekizumab versus adalimumab in plaque psoriasis

N Engl J Med 2021; 385:130–41. doi: 10.1056/NEJMoa2102388

Bimekizumab was noninferior and superior to adalimumab with respect to PASI 90 response and IGA score at Week 16. Bimekizumab is a promising IL-17A/F inhibitor that has shown clinical improvement in PsO patients compared to placebo and other IL inhibitors. Warren et al. compared the safety and efficacy of bimekizumab with adalimumab in a 56-week double-blind trial.

Keywords:

Deucravacitinib versus placebo and apremilast in moderate to severe plaque psoriasis: Efficacy and safety results from the 52-week, randomized, double-blinded, Phase 3 Program fOr Evaluation of TYK2 inhibitor psoriasis second trial

J Am Acad Dermatol 2023;88:40–51. doi: 10.1016/j.jaad.2022.08.061

This Phase 3 study by Strober, et al. reports deucravacitinib superiority to placebo and apremilast in patients with PsO. The authors found that deucravacitinib had significantly higher rates of PASI 75 and sPGA achievement than placebo and deucravacitinib.

Keywords:

Real-world experience of IL-17Ai drug survival in a large cohort of axial spondyloarthritis and psoriatic arthritis

Rheumatol Adv Pract 2024;8(1):rkae018 doi: 10.1093/rap/rkae018

This retrospective analysis by Weddell, et al. found no difference in IL-17Ai (secukinumab and ixekizumab) survival rates and no relationship between PsA or axSpA diagnosis and drug survival. They also noted lower survival figures at 2 years of treatment.

Keywords:

Effects of disease‑modifying anti‑rheumatic drugs on sacroiliac MRI score in axial spondyloarthritis: A systematic review and meta‑analysis

Clin Rheumatol 2024;43(3):1045–1052 doi: 10.1007/s10067-023-06849-5

The results of the meta-analysis show that TNFi, IL-17i, and JAK inhibitor treatments significantly improved sacroiliac joint SPARCC scores in patients with axSpA or AS at Weeks 12–16. However, there were no significant differences in mean improvement between the treatment groups.

Keywords:

Impact of the time of initiation and line of biologic therapy on the retention rate of secukinumab in axial spondyloarthritis (axSpA): Data from the French Multicentre Retrospective FORSYA Study

RMD Open. 2024; 10(1):e003942 DOI 10.1136/rmdopen-2023-003942

Patients in France who started secukinumab therapy further from the launch of secukinumab were more likely to receive it as a first- or second-line therapy than patients who started treatment shortly after its launch, and had a higher retention rate when used as a first line treatment.

Keywords:

March 2024

Abatacept inhibits inflammation and onset of rheumatoid arthritis in individuals at high risk (ARIAA): A randomised, international, multicentre, double-blind, placebo-controlled trial

Lancet 2024;403(10429):850–859 doi 10.1016/S0140-6736(23)02650-8

This study by Rech, et al. shows that 6-month treatment with abatacept was associated with a decrease in MRI inflammation, clinical symptoms, and risk of RA development in participants at high risk. The effects of the intervention persist through a 1-year drug-free observation phase.

Keywords:

Comparative Effectiveness of Tofacitinib and Tumour Necrosis Factor Inhibitors in Patients with Rheumatoid Arthritis in Real-world Practice: A Prospective Observational Study

doi: 10.1093/rheumatology/keae109 Epub ahead of print

This study by Cho, et al. did not find any significant differences in remission rates in South Korean patients with RA that were treated with tofacitinib versus TNFi in a real-world setting. Remission rates were significantly higher for patients naïve to both JAKi and bDMARDs treated with tofacitinib versus TNFi.

Keywords:

Association of the clinical components in the distal interphalangeal joint synovio-entheseal complex and subsequent response to ixekizumab or adalimumab in psoriatic arthritis

Rheumatology 2024 doi 10.1093/rheumatology/keae060 Epub ahead of print

This post hoc analysis of the SPIRIT-H2H study showed that patients with PsA that were treated with ixekizumab had significantly higher rates of symptom resolution versus adalimumab at Weeks 12 and 52 in distal interphalangeal joint disease and nail PsO.

Keywords:

Long term safety of ixekizumab in adults with psoriasis, psoriatic arthritis, or axial spondyloarthritis: A post hoc analysis of final safety data from 25 randomized clinical trials

Arthritis Res Ther 2024;26(1):49 doi: 10.1186/s13075-023-03257-7

Incident rates of TEAEs were comparable for patients with PsO, PsA, and axSpA and did not increase with prolonged ixekizumab (IXE) treatment. Deodhar, et al. presented the final update on the long-term safety of IXE up to 6 years in PsO patients and up to 3 years in PsA and axSpA patients. Exposure-adjusted incident rates were calculated using patient data (TEAEs, SAEs, selected AEs) from 25 clinical trials.

Keywords: